BioSpace News Archive

SpyBiotech announced that the company has filed a clinical trial application with the U.K. Medicines and Healthcare products Regulatory Agency to evaluate SPYVLP01, a vaccine targeting human cytomegalovirus using its Hepatitis B virus-like-particle platform technology.

CMR Surgical has announced that its next-generation Versius® Surgical Robotic System has been used to perform more than 15,000 surgeries globally.

Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI) today announced it will highlight new product innovations and present new interim data for the ALIGN3D™ clinical study at the American Orthopaedic Foot & Ankle Society (AOFAS) Annual Meeting 2023 in Louisville, Kentucky from September 20-23, 2023.

Merck announced the U.S. Food and Drug Administration has accepted for priority review a new supplemental Biologics License Application seeking approval for KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with external beam radiotherapy plus concurrent chemotherapy, followed by brachytherapy as treatment with definitive intent for newly diagnosed patients with high-risk locally advanced cervical cancer.

IceCure Medical Ltd. today announced that the U.S. Food and Drug Administration (“FDA”) has at this time denied the Company’s De Novo Classification request for breast cancer which was submitted based on interim analysis from its ICE3 study.

Orthofix Medical Inc., a leading global spine and orthopedics company, announced the full U.S. commercial launch and successful completion of the first cases with the Galaxy Fixation Gemini™ system.

Orionis Biosciences, a privately held life sciences company with an integrated drug discovery and chemical biology platform, announced today a multi-year collaboration with Genentech, a member of the Roche Group, to discover novel small molecule medicines for challenging targets in major disease areas, including oncology and neurodegeneration.

GE HealthCare released its inaugural Sustainability Report, which describes the steps the Company has taken to establish its stand-alone environmental, social, and governance practice and infrastructure, as well as how it has bolstered the foundation put in place prior to its spin-off from GE.

Bristol Myers Squibb announced that its Board of Directors has declared a quarterly dividend of fifty-seven cents per share on the $0.10 par value common stock of the company.

Olema Pharmaceuticals, Inc. ( “Olema” or “Olema Oncology,” Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted therapies for women’s cancers, today announced a poster presentation on new discovery compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers.